Clinical Pharmacological Study to Investigate the Effects of Mucosta Ophthalmic Suspension UD2% on Ocular Surface Cells in Patients with Dry Eye

Not Applicable

• Conditions: Dry eye

• Registration Number: JPRN-UMIN000022629
• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-06-10
• Study Completion: 2017-03-07
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients with any anterior segment eye disease such as blepharitis, lagophthalmos, blepharospasm, and iritis, except dry eye (Patients with past history of those diseases are acceptable.) 2.Patients to whom any ophthalmic drops (all prescription and OCT drugs included) are not able to be discontinued, or expected to be used from the start of the screening until the end of the study period. (Soft santear is acceptable during the screening period.) 3.Patients who cannot discontinue the use of contact lenses from the start of the screening until the end of the study period 4.Patients with punctal plugs 5.Patients who underwent any surgery on the ocular surface within 12 months or intraocular surgery within 3 months prior to the start of the screening 6.Patients with severe ocular disorder due to Stevens-Johnson syndrome or ocular pemphigoid 7.Patients who are pregnant, lactating, or may be pregnant 8.Patients with hypersensitivity reaction to components of the study drug or test agents used in this study 9.Patients whom investigatoror sub-investigatorconsidered not to be able to include the study because of prior or complicated systemic disease 10.Patients participating in another clinical study or trial 11.Others who areconsidered inappropriate for the study by investigatoror sub-investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified